Diabetic Gastroparesis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Diabetic Gastroparesis – Pipeline Review, H1 2017’, provides an overview of the Diabetic Gastroparesis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis

– The report reviews pipeline therapeutics for Diabetic Gastroparesis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Diabetic Gastroparesis therapeutics and enlists all their major and minor projects

– The report assesses Diabetic Gastroparesis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Gastroparesis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Gastroparesis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Cempra Inc

Evoke Pharma Inc

GlaxoSmithKline Plc

Motus Therapeutics Inc

Shire Plc

Theravance Biopharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Diabetic Gastroparesis - Overview

Diabetic Gastroparesis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Diabetic Gastroparesis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Gastroparesis - Companies Involved in Therapeutics Development

Cempra Inc

Evoke Pharma Inc

GlaxoSmithKline Plc

Motus Therapeutics Inc

Shire Plc

Theravance Biopharma Inc

Diabetic Gastroparesis - Drug Profiles

camicinal - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEM-031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETX-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETX-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metoclopramide hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prucalopride succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relamorelin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

renzapride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate nNOS for Diabetic Gastroparesis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

velusetrag hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Diabetic Gastroparesis - Dormant Projects

Diabetic Gastroparesis - Discontinued Products

Diabetic Gastroparesis - Product Development Milestones

Featured News & Press Releases

Jan 04, 2017: Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial

Dec 15, 2016: Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti

Dec 06, 2016: Theravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis

Sep 07, 2016: Evoke Pharma Announces Positive Non-Clinical Pre-NDA Meeting with FDA for Gimoti

Jul 26, 2016: Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001

Jul 18, 2016: Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial

Jul 07, 2016: Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement

Jun 01, 2016: Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis

May 24, 2016: Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016

May 19, 2016: Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001

May 03, 2016: Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001

Apr 25, 2016: Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis

Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis

Mar 03, 2016: Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts

Mar 01, 2016: Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Diabetic Gastroparesis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Diabetic Gastroparesis – Pipeline by Cempra Inc, H1 2017

Diabetic Gastroparesis – Pipeline by Evoke Pharma Inc, H1 2017

Diabetic Gastroparesis – Pipeline by GlaxoSmithKline Plc, H1 2017

Diabetic Gastroparesis – Pipeline by Motus Therapeutics Inc, H1 2017

Diabetic Gastroparesis – Pipeline by Shire Plc, H1 2017

Diabetic Gastroparesis – Pipeline by Theravance Biopharma Inc, H1 2017

Diabetic Gastroparesis – Dormant Projects, H1 2017

Diabetic Gastroparesis – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Diabetic Gastroparesis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports